Oct 30 (Reuters) - Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Savio D'Souza)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | 0.00% | -20.33% | -66.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.89% | 47.74M | |
+33.37% | 49.46B | |
+1.75% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.58% | 26.61B | |
-21.80% | 18.64B | |
+7.87% | 13.16B | |
+29.73% | 12.55B | |
+23.58% | 12.1B |
- Stock Market
- Equities
- RVPH Stock
- News Reviva Pharmaceuticals Holdings, Inc.
- Reviva Pharma's schizophrenia drug succeeds in late-stage study